[1]
|
Brunton, S. (2016) Pathophysiology of Type 2 Diabetes: The Evolution of Our Understanding. The Journal of Family Practice, 65.
|
[2]
|
DeFronzo, R.A., Eldor, R. and Abdul-Ghani, M. (2013) Pathophysiologic Approach to Therapy in Patients with Newly Diagnosed Type 2 Diabetes. Diabetes Care, 36, S127-S138. https://doi.org/10.2337/dcS13-2011
|
[3]
|
Hugenschmidt, C.E. (2013) A Link between Type 2 Diabetes and Brain Function. Journal of the American Academy of Physician Assistants, 26, 10-11. https://doi.org/10.1097/01.JAA.0000437750.76865.61
|
[4]
|
Zaccardi, F., Webb, D.R., Yates, T. and Davies, M.J. (2016) Pathophysiology of Type 1 and Type 2 Diabetes Mellitus: A 90-Year Perspective. Postgraduate Medical Journal, 92, 63-69. https://doi.org/10.1136/postgradmedj-2015-133281
|
[5]
|
Javeed, N. and Matveyenko, A.V. (2018) Circadian Etiology of Type 2 Diabetes Mellitus. Physiology, 33, 138-150. https://doi.org/10.1152/physiol.00003.2018
|
[6]
|
Henning, R.J. (2018) Type-2 Diabetes Mellitus and Cardiovascular Disease. Future Cardiology, 14, 491-509. https://doi.org/10.2217/fca-2018-0045
|
[7]
|
Kabadi, U.M. (2017) Major Pathophysiology in Prediabetes and Type 2 Diabetes: Decreased Insulin in Lean and Insulin Resistance in Obese. Journal of the Endocrine Society, 1, 742-750. https://doi.org/10.1210/js.2016-1116
|
[8]
|
Barnett, R. (2018) Type 1 Diabetes. The Lancet, 391, 195. https://doi.org/10.1016/S0140-6736(18)30024-2
|
[9]
|
(2018) What You Should Know About Type 1 Diabetes. American Family Physician, 1, 1997-1998.
|
[10]
|
Dayan, C.M., Korah, M., Tatovic, D., Bundy, B.N. and Herold, K.C. (2019) Changing the Landscape for Type 1 Diabetes: The First Step to Prevention. The Lancet, 394, 1286-1296. https://doi.org/10.1016/S0140-6736(19)32127-0
|
[11]
|
Korytkowski, M., Thomas, A., Reid, L., et al. (2002) Glimepiride Improves Both First and Second Phases of Insulin Secretion in Type 2 Diabetes. Diabetes Care, 25, 1607-1611. https://doi.org/10.2337/diacare.25.9.1607
|
[12]
|
Kabadi, M.U. and Kabadi, U.M. (2004) Effects of Glimepiride on Insulin Secretion and Sensitivity in Patients with Recently Diagnosed type 2 Diabetes Mellitus. Clinical Therapeutics, 26, 63-69. https://doi.org/10.1016/S0149-2918(04)90006-9
|
[13]
|
Kabadi, U.M. and Kabadi, M. (2011) Early Postprandial Insulin Secretion: Its Relation to Insulin Sensitivity. Journal of Diabetes Mellitus, 1, 1-5. https://doi.org/10.4236/jdm.2011.11001
|
[14]
|
Kabadi, U., Kabadi, M.U., Weber, S., Bubolz, A. and Finnerty, E. (2015) Progressive β-Cell Failure in Type 2 Diabetes Mellitus: Microvascular Pancreatic Isletopathy? Journal of Diabetes Mellitus, 5, 21-27. https://doi.org/10.4236/jdm.2015.51003
|
[15]
|
Kabadi, U. (2017) Major Pathophysiology in Prediabetes and Type 2 Diabetes: Decreased Insulin in Lean and Insulin Resistance in Obese. Journal of the Endocrine Society, 1, 742-750. https://doi.org/10.1210/js.2016-1116
|
[16]
|
Cinti, F., Bouchi, R., Kim-Muller, J.Y., et al. (2016) Dysfunction of Pancreatic Beta Cells: Dedifferentiation into Other Empty Cells. The Journal of Clinical Endocrinology & Metabolism, 101, 1048-1054.
|
[17]
|
UK Prospective Diabetes Study Group (1998) Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). The Lancet, 352, 837-853. https://doi.org/10.1016/S0140-6736(98)07019-6
|
[18]
|
UK Prospective Diabetes Study Group (1998) Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34). The Lancet, 352, 854-865. https://doi.org/10.1016/S0140-6736(98)07037-8
|
[19]
|
UK Prospective Diabetes Study Group (1995) U.K. Prospective Diabetes Study 16: Overview of 6 Years’ Therapy of Type II Diabetes: A Progressive Disease. Diabetes, 44, 1249-1258. https://doi.org/10.2337/diab.44.11.1249
|
[20]
|
Kabadi, U.M. (2002) United Kingdom Prospective Diabetes Study: A Different Perspective. Endocrine Practice, 8, 61. https://doi.org/10.4158/EP.8.1.61
|
[21]
|
Jain, R., Kabadi, U. and Kabadi, M. (2008) Is Beta Cell Failure in Type 2 DM Reversible? International Journal of Diabetes in Developing Countries, 28, 1-5.
|
[22]
|
Kabadi, U.M. and Exley, S. (2018) Progressive Beta Cell Failure in Type 2 Diabetes: Influence of Aging and Not Duration of Diabetes. International Congress of Endocrinology, Abstract ID: 366.
|
[23]
|
Banzal, S. and Kabadi, U.M. (2019) Better Glycemic Control with Less Insulin on Transition from Continuous Subcutaneous Insulin Infusion to Basal Insulin Combined GLP1 Receptor Agonist and/or Metformin and Sulfonylurea. Journal of Diabetes, Obesity and Metabolism, 2, 1-8.
|
[24]
|
Kabadi, U.M. (2013) Comparative Efficacy between Glimepiride and Metformin in Preventing Progression of Prediabetes to Type 2 Diabetes. Journal of Diabetes Mellitus, 3, 129-133. https://doi.org/10.4236/jdm.2013.33019
|
[25]
|
Kabadi, U.M. (1993) Hepatic Regulation of Pancreatic Alpha-Cell Function. Metabolism, 42, 535-543. https://doi.org/10.1016/0026-0495(93)90208-6
|
[26]
|
Lee, Y.H., Wang, M.Y., Yu, X.X. and Unger, R.H. (2016) Glucagon Is the Key Factor in the Development of Diabetes. Diabetologia, 59, 1372-1375. https://doi.org/10.1007/s00125-016-3965-9
|
[27]
|
Holst, J.J., Holland, W., Gromada, J., Lee, Y., Unger, R.H., Yan, H., Sloop, K.W., Kieffer, T.J., Damond, N. and Herrera, P.L. (2017) Insulin and Glucagon: Partners for Life. Endocrinology, 158, 696-701. https://doi.org/10.1210/en.2016-1748
|
[28]
|
Stern, J.H., Smith, G.I., Chen, S., Unger, R.H., Klein, S. and Scherer, P.E. (2019) Obesity Dysregulates Fasting-Induced Changes in Glucagon Secretion. Journal of Endocrinology, 243, 149-160. https://doi.org/10.1530/JOE-19-0201
|
[29]
|
Ichikawa, R., Takano, K., Fujimoto, K., Motomiya, T., Kobayashi, M., Kitamura, T. and Shichiri, M. (2019) Basal Glucagon Hypersecretion and Response to Oral Glucose Load in Prediabetes and Mild Type 2 Diabetes. Endocrine Journal, 29, 663-675.
|
[30]
|
Nicolai, J., Albrechtsen, W., Pedersen, J., Galsgaard, K.D., Winther-Sørensen, M., Suppli, M.P., Janah, L., Gromada, J., Vilstrup, H., Knop, F.K. and Holst, J.J. (2019) The Liver-α-Cell Axis and Type 2 Diabetes. Endocrine Reviews, 40, 1353-1366. https://doi.org/10.1210/er.2018-00251
|
[31]
|
Komada, H., Hirota, Y. and Ogawa, W. (2019) Glucagon Secretions Are Impaired in Patients with Fulminant Type 1 Diabetes. Journal of Diabetes Investigation, 10, 866-867. https://doi.org/10.1111/jdi.13041
|
[32]
|
Nauck, M.A. and Meier, J.J. (2016) The Incretin Effect in Healthy Individuals and those with Type 2 Diabetes: Physiology, Pathophysiology, and Response to Therapeutic Interventions. Lancet Diabetes & Endocrinology, 4, 525-536. https://doi.org/10.1016/S2213-8587(15)00482-9
|
[33]
|
Holst, J.J., Albrechtsen, N.J.W., Rosenkilde, M.M. and Deacon, C.F. (2019) Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications. Comprehensive Physiology, 9, 1339-1381. https://doi.org/10.1002/cphy.c180013
|
[34]
|
Holst, J.J. (2019) The Incretin System in Healthy Humans: The Role of GIP and GLP-1. Metabolism, 96, 46-55. https://doi.org/10.1016/j.metabol.2019.04.014
|
[35]
|
Shah, F.A., Mahmud, H., Gallego-Martin, T., Jurczak, M.J., O’Donnell, C.P. and McVerry, B.J. (2019) Therapeutic Effects of Endogenous Incretin Hormones and Exogenous Incretin-Based Medications in Sepsis. Journal of Clinical Endocrinology & Metabolism, 104, 5274-5284. https://doi.org/10.1210/jc.2019-00296
|
[36]
|
Chia, C.W. and Egan, J.M. (2020) Incretins in Obesity and Diabetes. Annals of the New York Academy of Sciences, 1461, 104-126. https://doi.org/10.1111/nyas.14211
|
[37]
|
Barchetta, I., Ciccarelli, G., Barone, E., Cimini, F.A., Ceccarelli, V., Bertoccini, L., Sentinelli, F., Tramutola, A., Del, B.M., Angelico, F., Baroni, M.G., Lenzi, A. and Cavallo, M.G. (2019) Greater Circulating DPP4 Activity Is Associated with Impaired Flow-Mediated Dilatation in Adults with Type 2 Diabetes Mellitus. Nutrition, Metabolism and Cardiovascular Diseases, 29, 1087-1094. https://doi.org/10.1016/j.numecd.2019.07.010
|
[38]
|
Sarkar, J., Nargis, T., Tantia, O., Ghosh, S. and Chakrabarti, P. (2019) Increased Plasma Dipeptidyl Peptidase-4 (DPP4) Activity Is an Obesity-Independent Parameter for Glycemic Deregulation in Type 2 Diabetes Patients. Frontiers in Endocrinology, 10, 505. https://doi.org/10.3389/fendo.2019.00505
|
[39]
|
Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G. and Rotella, C.M. (2001) Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects. Diabetes Care, 24, 489-494. https://doi.org/10.2337/diacare.24.3.489
|
[40]
|
Green, B.D., Irwin, N., Duffy, N.A., Gault, V.A., O’harte, F.P.M. and Flatt, P.R. (2006) Inhibition of Dipeptidyl Peptidase-IV Activity by Metformin Enhances the Antidiabetic Effects of Glucagon-Like Peptide-1. European Journal of Pharmacology, 547, 192-199. https://doi.org/10.1016/j.ejphar.2006.07.043
|
[41]
|
Mulherin, A.J., Oh, A.H., Kim, H., Grieco, A., Lauffer, L.M. and Brubaker, P.L. (2011) Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell. Endocrinology, 152, 4610-4619. https://doi.org/10.1210/en.2011-1485
|
[42]
|
Eshghi, S.R.T., Bell, G.J. and Boulé, N.G. (2013) Effects of Aerobic Exercise with or without Metformin on Plasma Incretins in Type 2 Diabetes. Canadian Journal of Diabetes, 37, 375-380. https://doi.org/10.1016/j.jcjd.2013.07.030
|
[43]
|
Wu, T., Thazhath, S.S., Bound, M.J., Jones, K.L., Horowitz, M. and Rayner, C.K. (2014) Mechanism of Increase in Plasma Intact GLP-1 by Metformin in Type 2 Diabetes: Stimulation of GLP-1 Secretion or Reduction in Plasma DPP-4 Activity? Diabetes Research and Clinical Practice, 106, e3-e6. https://doi.org/10.1016/j.diabres.2014.08.004
|
[44]
|
Bahne, E., Hansen, M., Brønden, A., Sonne, D.P., Vilsbøll, T. and Knop F.K. (2016) Involvement of Glucagon-Like Peptide-1 in the Glucose-Lowering Effect of Metformin. Diabetes, Obesity and Metabolism, 18, 955-961. https://doi.org/10.1111/dom.12697
|
[45]
|
Capozzi, M.E., DiMarchi, R.D., Tschöp, M.H., Finan, B. and Campbell, J.E. (2018) Targeting the Incretin/Glucagon System with Triagonists to Treat Diabetes. Endocrine Reviews, 39, 719-738. https://doi.org/10.1210/er.2018-00117
|
[46]
|
Nguyen, T., Gong, M., Wen, S., Yuan, X., Wang, C., Jin, J. and Zhou, L. (2020) The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2020, Article ID: 4727390. https://doi.org/10.1155/2020/4727390
|
[47]
|
Alsalim, W., Göransson, O., Tura, A., Pacini, G., Mari, A. and Ahrén, Bo. (2020) Persistent Whole Day Meal Effects of Three Dipeptidyl Peptidase-4 Inhibitors on Glycaemia and Hormonal Responses in Metformin-Treated Type 2 Diabetes. Diabetes, Obesity and Metabolism, 22, 590-598. https://doi.org/10.1111/dom.13934
|
[48]
|
Lonovics, J., Devitt, P., Watson, L.C., Rayford, P.L. and Thompson, J.C. (1981) Pancreatic Polypeptide. A Review. Archives of Surgery, 116, 1256-1264. https://doi.org/10.1001/archsurg.1981.01380220010002
|
[49]
|
Valicherla, G.R., Hossain, Z., Mahata, S.K. and Gayen, J.R. (2013) Pancreastatin Is an Endogenous Peptide That Regulates Glucose Homeostasis. Physiological Genomics, 45, 1060-1071. https://doi.org/10.1152/physiolgenomics.00131.2013
|
[50]
|
Westermark, P., Andersson, A. and Westermark, G.T. (2011) Islet Amyloid Polypeptide, Islet Amyloid, and Diabetes Mellitus. Physiological Reviews, 91, 795-826. https://doi.org/10.1152/physrev.00042.2009
|
[51]
|
Yadav, D., Nair, S., Norkus, E.P. and Pitchumoni, C.S. (2000) Non Specific Hyperamylasemia and Hyperlipasemia in Diabetic Ketoacidosis: Incidence and Correlation with Biochemical Abnormalities. American Journal of Gastroenterology, 95, 3123-3128.
|
[52]
|
Quiros, J.A., Marcin, J.P., Kuppermann, N., Nasrollahzadeh, F., Rewers, A., DiCarlo, J., Neely, E.K. and Glaser, N. (2008) Elevated Serum Amylase and Lipase in Pediatric Diabetic Ketoacidosis. Pediatric Critical Care Medicine, 9, 418-422. https://doi.org/10.1097/PCC.0b013e318172e99b
|
[53]
|
Campbell-Thompson, M., Rodriguez-Calvo, T. and Battaglia, M. (2015) Abnormalities of the Exocrine Pancreas in Type 1 Diabetes. Current Diabetes Reports, 15, Article No. 79. https://doi.org/10.1007/s11892-015-0653-y
|
[54]
|
Mohapatra, S., Majumder, S., Smyrk, T.C., Zhang, L., Matveyenko, A., Kudva, Y.C. and Chari, S.T. (2016) Diabetes Mellitus Is Associated With an Exocrine Pancreatopathy: Conclusions From a Review of Literature. Pancreas, 45, 1104-1110. https://doi.org/10.1097/MPA.0000000000000609
|
[55]
|
Larger, E., Philippe, M.F., Barbot-Trystram, L., Radu, A., Rotariu, M., Nobécourt, E. and Boitard, C. (2012) Pancreatic Exocrine Function in Patients with Diabetes. Diabetic Medicine, 29, 1047-1054. https://doi.org/10.1111/j.1464-5491.2012.03597.x
|
[56]
|
Radlinger, B., Ramoser, G. and Kaser, S. (2020) Exocrine Pancreatic Insufficiency in Type 1 and Type 2 Diabetes. Current Diabetes Reports, 20, Article No. 18. https://doi.org/10.1007/s11892-020-01304-0
|
[57]
|
Tilg, H., Moschen, A.R. and Roden, M. (2017) NAFLD and Diabetes Mellitus. Nature Reviews Gastroenterology & Hepatology, 14, 32-42. https://doi.org/10.1038/nrgastro.2016.147
|
[58]
|
Radaelli, M.G., Martucci, F., Perra, S., Accornero, S., Castoldi, G., Lattuada, G., Manzoni, G. and Perseghin, G. (2018) NAFLD/NASH in Patients with Type 2 Diabetes and Related Treatment Options. Journal of Endocrinological Investigation, 41, 509-521. https://doi.org/10.1007/s40618-017-0799-3
|
[59]
|
Younossi, Z.M., Tampi, R.P., Racila, A., Qiu, Y., Burns, L., Younossi, I. and Nader, F. (2020) Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.. Diabetes Care, 43, 283-289. https://doi.org/10.2337/dc19-1113
|
[60]
|
Taskinen, M.R. and Borén, J. (2015) New Insights into the Pathophysiology of Dyslipidemia in Type 2 Diabetes. Atherosclerosis, 239, 483-495. https://doi.org/10.1016/j.atherosclerosis.2015.01.039
|
[61]
|
Bulut, T., Demirel, F. and Metin, A. (2017) The Prevalence of Dyslipidemia and Associated Factors in Children and Adolescents with Type 1 Diabetes. Journal of Pediatric Endocrinology and Metabolism, 30, 181-187. https://doi.org/10.1515/jpem-2016-0111
|
[62]
|
Athyros, V.G., Doumas, M., Imprialos, K.P., Stavropoulos, K., Georgianou, E., Katsimardou, A. and Karagiannis, A. (2018) Diabetes and Lipid Metabolism. Hormones, 17, 61-67. https://doi.org/10.1007/s42000-018-0014-8
|
[63]
|
Shahwan, M.J., Jairoun, A.A., Farajallah, A. and Shanabli, S. (2019) Prevalence of Dyslipidemia and Factors Affecting Lipid Profile in Patients with Type 2 Diabetes. Diabetology & Metabolic Syndrome, 13, 2387-2392. https://doi.org/10.1016/j.dsx.2019.06.009
|
[64]
|
Sobczak, A.I.S., Blindauer, C.A. and Stewart, A.J. (2019) Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes. Nutrients, 11, 2022. https://doi.org/10.3390/nu11092022
|
[65]
|
Lazarte, J. and Hegele, R.A. (2020) Dyslipidemia Management in Adults with Diabetes. Canadian Journal of Diabetes, 44, 53-60. https://doi.org/10.1016/j.jcjd.2019.07.003
|
[66]
|
Knebel, B., Strassburger, K., Szendroedi, J., Kotzka, J., Scheer, M., Nowotny, B., Müssig, K., Lehr, S., Pacini, G., Finner, H., Klüppelholz, B., Giani, G., Al-Hasani, H. and Roden, M., for the German Diabetes Study Group (2016) Specific Metabolic Profiles and Their Relationship to Insulin Resistance in Recent-Onset Type 1 and Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 101, 2130-2140. https://doi.org/10.1210/jc.2015-4133
|
[67]
|
Derosa, G., Mugellini, A., Ciccarelli, L., Crescenzi, G. and Fogari, R. (2003) Comparison between Repaglinide and Glimepiride in Patients with Type 2 Diabetes Mellitus: A One-Year, Randomized, Double-Blind Assessment of Metabolic Parameters and Cardiovascular Risk Factors. Clinical Therapeutics, 25, 472-484. https://doi.org/10.1016/S0149-2918(03)80090-5
|
[68]
|
Kabadi, U.M. and Kabadi, M.U. (2001) Improvement in Lipids with Glimepiride in Type 2 Diabetes Mellitus. Journal of Diabetes Research, 35, 155.
|
[69]
|
Esmail, R. and Kabadi, U.M. (2016) Improvement in Cardiovascular Risk Markers with Glimepiride in Non Obese Subjects with Pre Diabetes: Similar to Obese Cohort Treated with Metformin. British Journal of Medicine & Medical Research, 18, 1-6.
|
[70]
|
Calle, M.C. and Fernandez, M.L. (2012) Inflammation and Type 2 Diabetes. Diabetes & Metabolism, 38, 183-191. https://doi.org/10.1016/j.diabet.2011.11.006
|
[71]
|
Stefan, N. and Haring, H. (2013) The Role of Hepatokines in Metabolism. Nature Reviews Endocrinology, 9, 144–152. https://doi.org/10.1038/nrendo.2012.258
|
[72]
|
Hansen, J.S., Pedersen, B.K., Xu, G., Lehmann, R., Weigert, C. and Plomgaard, P. (2016) Exercise-Induced Secretion of FGF21 and Follistatin Are Blocked by Pancreatic Clamp and Impaired in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 101, 2816-2825. https://doi.org/10.1210/jc.2016-1681
|
[73]
|
Shruthi, S., Mohan, V., Amutha, A. and Aravindhan, V. (2016) Increased Serum Levels of Novel T Cell Cytokines IL-33, IL-9 and IL-17 in Subjects with Type-1 Diabetes. Cytokine, 86, 6-9. https://doi.org/10.1016/j.cyto.2016.07.007
|
[74]
|
Brahimaj, A., Ligthart, S., Ghanbari, M., Ikram, M.A., Hofman, A., Franco, O.H., Kavousi, M. and Dehghan, A. (2017) Novel Inflammatory Markers for Incident Pre-Diabetes and Type 2 Diabetes: The Rotterdam Study. European Journal of Epidemiology, 32, 217-226. https://doi.org/10.1007/s10654-017-0236-0
|
[75]
|
Reinehr, T. and Roth, C.L. (2018) Inflammation Markers in Type 2 Diabetes and the Metabolic Syndrome in the Pediatric Population. Current Diabetes Reports, 18, Article No. 131. https://doi.org/10.1007/s11892-018-1110-5
|
[76]
|
Borzouei, S., Sheikh, V., Ghasemi, M., Zamani, A., Telikani, Z., Zareighane, Z., Salehi, I., Mozayanimonfared, A., Amirzargar, M.A. and Alahgholi-Hajibehzad, M. (2019) Anti-Inflammatory Effect of Combined Sitagliptin and Vitamin D3 on Cytokines Profile in Patients with Type 2 Diabetes Mellitus. Journal of Interferon & Cytokine Research, 39, 293-301. https://doi.org/10.1089/jir.2018.0144
|
[77]
|
Mazidi, M., Karimi, E., Rezaie, P. and Ferns, G.A. (2017) Treatment with GLP1 Receptor Agonists Reduce Serum CRP Concentrations in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes and its Complications, 31, 1237-1242. https://doi.org/10.1016/j.jdiacomp.2016.05.022
|
[78]
|
Zóka, A. Barna, G., Hadarits, O., Al-Aissa, Z., Wichmann, B., Műzes, G., Somogyi, A. and Firneisz, G. (2015) Altered Crosstalk in the Dipeptidyl Peptidase-4-Incretin-Immune System in Type 1 Diabetes: A Hypothesis Generating Pilot Study. Human Immunology, 76, 667-672. https://doi.org/10.1016/j.humimm.2015.09.018
|
[79]
|
Karbalaee-Hasani, A., Khadive, T., Eskandari, M., Shahidi, S., Mosavi, M., Nejadebrahimi, Z., Khalkhali, L., Sangdari, A., Mohammadi, D., Soltani, A., Khodabandehloo, H., Hosseini, H. and Koushki, M. (2021) Effect of Metformin on Circulating Levels of Inflammatory Markers in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Annals of Pharmacotherapy. https://doi.org/10.1177/1060028020985303
|
[80]
|
Kershaw, E.E. and Flier, J.S. (2004) Adipose Tissue as an Endocrine Organ. Journal of Clinical Endocrinology & Metabolism, 89, 2548-2556. https://doi.org/10.1210/jc.2004-0395
|
[81]
|
Fasshauer, M. and Blüher, M. (2015) Adipokines in Health and Disease. Trends in Pharmacological Sciences, 36, 461-470. https://doi.org/10.1016/j.tips.2015.04.014
|
[82]
|
López-Jaramillo, P., Gómez-Arbeláez, D., López-López, J., López-López, C., Martínez-Ortega, J., Gómez-Rodríguez, A. and Triana-Cubillos, S. (2014) The Role of Leptin/Adiponectin Ratio in Metabolic Syndrome and Diabetes. Hormone Molecular Biology and Clinical Investigation, 18, 37-45. https://doi.org/10.1515/hmbci-2013-0053
|
[83]
|
Lau, W.B., Ohashi, K., Wang, Y., Ogawa, H., Murohara, T., Ma, X.L. and Ouchi, N. (2017) Role of Adipokines in Cardiovascular Disease. Circulation Journal, 81, 920-928.
|
[84]
|
Baldauff, N.H., Tfayli, H., Dong, W., et al. (2016) Relationship of Adiponectin and Leptin with Autoimmunity in Children with New-Onset Type 1 Diabetes: A Pilot Study. Pediatric Diabetes, 17, 249-256. https://doi.org/10.1111/pedi.12267
|
[85]
|
Leth, H., Andersen, K.K., Frystyk, J., Tarnow, L., Rossing, P., Parving, H.H. and Flyvbjerg, A. (2008) Elevated Levels of High-Molecular-Weight Adiponectin in Type 1 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 93, 3186-3191. https://doi.org/10.1210/jc.2008-0360
|
[86]
|
Kumar, S., Hossain, J., Nader, N., Aguirre, R., Sriram, S. and Balagopal, B.P. (2016) Decreased Circulating Levels of Spexin in Obese Children. The Journal of Clinical Endocrinology & Metabolism, 101, 2931-2936. https://doi.org/10.1210/jc.2016-1177
|
[87]
|
Elbert, T., Gebhardt, C., Scholz, M., et al. (2018) Relationship between 12 Adipocytokines and Distinct Components of Metabolic Syndrome. The Journal of Clinical Endocrinology & Metabolism, 103, 1015-1023. https://doi.org/10.1210/jc.2017-02085
|
[88]
|
Yin, C.Y., Hu, W., Wang M. and Xiao, Y.F. (2019) The Role of the Adipocytokines Vaspin and Visfatin in Vascular Endothelial Function and Insulin Resistance in Obese Children. BMC Endocrine Disorders, 19, 127. https://doi.org/10.1186/s12902-019-0452-6
|
[89]
|
Perez-Sotelo, D., Roca-Rivada, A., Larrosa-Garcia, M., Castelao, C., Baamonde, I., Baltar, J., Crujeiras, A.B., Seoane, L.M., Casanueva, F.F. and Pardo, M. (2017) Visceral and Subcutaneous Adipose Tissue Express and Secrete Functional Alpha2hsglycoprotein (Fetuin a) Especially in Obesity. Endocrine, 55, 435-446. https://doi.org/10.1007/s12020-016-1132-1
|
[90]
|
Jiala, I., Devaraj, S., Bettaieb, A., Haj, F. and Adams-Huet, B. (2015) Increased Adipose Tissue Secretion of Fetuin-A, Lipopolysaccharide-Binding Protein and High-Mobility Group Box Protein 1 in Metabolic Syndrome. Atherosclerosis, 241, 130-137. https://doi.org/10.1016/j.atherosclerosis.2015.04.814
|
[91]
|
Liu, S., Hu, W., He, Y., Li, L., Liu, H., Gao, L., Yang G. and Liao, X. (2020) Serum Fetuin-A Levels Are Increased and Associated with Insulin Resistance in Women with Polycystic Ovary Syndrome. BMC Endocrine Disorders, 20, Article No. 67. https://doi.org/10.1186/s12902-020-0538-1
|
[92]
|
Liang, W. and Ye, D.D. (2019) The Potential of Adipokines as Biomarkers and Therapeutic Agents for Vascular Complications in Type 2 Diabetes Mellitus. Cytokine & Growth Factor Reviews, 48, 32-39. https://doi.org/10.1016/j.cytogfr.2019.06.002
|
[93]
|
Heliövaara, M.K., Teppo, A.M., Karonen, S.L., Tuominen, J.A. and Ebeling, P. (2006) Improved Glycaemia in Type 1 Diabetes Results in Decreased Levels of Soluble Adhesion Molecules with No Change in Serum Adiponectin or Most Acute Phase Proteins. Experimental and Clinical Endocrinology & Diabetes, 114, 295-300. https://doi.org/10.1055/s-2006-924265
|
[94]
|
Galler, A., Gelbrich, G., Kratzsch, J., Noack, N., Kapellen, T. and Kiess, W. (2007) Elevated Serum Levels of Adiponectin in Children, Adolescents and Young Adults with Type 1 Diabetes and the Impact of Age, Gender, Body Mass Index and Metabolic Control: A Longitudinal Study. European Journal of Endocrinology, 157, 481-489. https://doi.org/10.1530/EJE-07-0250
|
[95]
|
Tsunekawa, T., Hayashi, T., Suzuki, Y., Matsui-Hirai, H., Kano, H., Fukatsu, A., Nomura, N., Miyazaki, A. and Iguchi, A. (2003) Plasma Adiponectin Plays an Important Role in Improving Insulin Resistance with Glimepiride in Elderly Type 2 Diabetic Subjects. Diabetes Care, 26, 285-289. https://doi.org/10.2337/diacare.26.2.285
|
[96]
|
Alba-Loureiro, T.C., Munhoz, C.D., Martins, J.O., Cerchiaro, G.A., Scavone, C., Curi, R. and Sannomiya, P. (2007) Neutrophil Function and Metabolism in Individuals with Diabetes Mellitus. Brazilian Journal of Medical and Biological Research, 40, 1037-1044. https://doi.org/10.1590/S0100-879X2006005000143
|
[97]
|
Hanley, A.J., Retnakaran, R., Qi, Y., Gerstein, H.C., Perkins, B., Raboud, J., Harris, S.B. and Zinman, B. (2009) Association of Hematological Parameters with Insulin Resistance and Beta-Cell Dysfunction in Nondiabetic Subjects. The Journal of Clinical Endocrinology & Metabolism, 94, 3824-3832. https://doi.org/10.1210/jc.2009-0719
|
[98]
|
Rao, X., Zhong, J. and Sun, Q. (2014) The Heterogenic Properties of Monocytes/Macrophages and Neutrophils in Inflammatory Response in Diabetes. Life Sciences, 116, 59-66. https://doi.org/10.1016/j.lfs.2014.09.015
|
[99]
|
Menegazzo, L., Ciciliot, S., Poncina, N., Mazzucato, M., Persano, M., Bonora, B., Albiero, M., Kreutzenberg, V.S., Avogaro, A. and Fadini, G.P. (2015) NETosis Is Induced by High Glucose and Associated with Type 2 Diabetes. Acta Diabetologica, 52, 497-503. https://doi.org/10.1007/s00592-014-0676-x
|
[100]
|
Kolseth, I.B., Reine, T.M., Parker, K., Sudworth, A., Witczak, B.J., Jenssen, T.G. and Kolset, S.O. (2017) Increased Levels of Inflammatory Mediators and Proinflammatory Monocytes in Patients with Type I Diabetes Mellitus and Nephropathy. Journal of Diabetes and its Complications, 31, 245-252. https://doi.org/10.1016/j.jdiacomp.2016.06.029
|
[101]
|
Szablewski, L. and Sulima, A. (2017) The Structural and Functional Changes of Blood Cells and Molecular Components in Diabetes Mellitus. Journal of Biological Chemistry, 398, 411-423. https://doi.org/10.1515/hsz-2016-0196
|
[102]
|
Gajos, G., Siniarski, A., Natorska, J., Ząbczyk, M., Siudut, J., Malinowski, K.P., Gołębiowska-Wiatrak, R., Rostoff, P. and Undas, A. (2018) Polyhedrocytes in Blood Clots of Type 2 Diabetic Patients with High Cardiovascular Risk: Association with Glycemia, Oxidative Stress and Platelet Activation. Cardiovascular Diabetology, 17, 146. https://doi.org/10.1186/s12933-018-0789-6
|
[103]
|
Nagalievska, M., Sabadashka, M., Hachkova, H. and Sybirna, N. (2018) Galega Officinalis Extract Regulate the Diabetes Mellitus Related Violations of Proliferation, Functions and Apoptosis of Leukocytes. BMC Complementary Medicine and Therapies, 18, Article No. 4. https://doi.org/10.1186/s12906-017-2079-3
|
[104]
|
Eastman, D.K., Bottenberg, M.M., Hegge, K.A., Ourth, H. and Kabadi, U. (2009) Intensive Insulin Therapy in Critical Care Settings. Current Clinical Pharmacology, 4, 71-77. https://doi.org/10.2174/157488409787236100
|
[105]
|
Picard, F., Adjedj, J. and Varenne, O. (2017) Diabetes Mellitus, a Prothrombotic Disease. Annales de Cardiologie et d’Angéiologie, 66, 385-392. https://doi.org/10.1016/j.ancard.2017.10.011
|
[106]
|
Li, Q., Li, L. and Li, Y. (2015) Enhanced RBC Aggregation in Type 2 Diabetes Patients. Journal of Clinical Laboratory Analysis, 29, 387-389. https://doi.org/10.1002/jcla.21784
|
[107]
|
Vasquez, B.Y., Vázquez, M.A., Jáquez, M.G., Huemoeller, A.H., Intaglietta, M. and Cabrales, P. (2010) Blood Pressure Directly Correlates with Blood Viscosity in Diabetes Type 1 Children but Not in Normals. Clinical Hemorheology and Microcirculation, 44, 55-61. https://doi.org/10.3233/CH-2010-1252
|
[108]
|
Irace, C., Carallo, C., Scavelli, F., Franceschi, M.S., Esposito, T. and Gnasso, A. (2014) Blood Viscosity in Subjects with Normoglycemia and Prediabetes. Diabetes Care, 37, 488-492. https://doi.org/10.2337/dc13-1374
|
[109]
|
Mazhara, M., Muhammada, A.M. and Uh-Hyunb, K. (2019) Hyperglycemia Associated Blood Viscosity Can Be a Nexus Stimuli. Clinical Hemorheology and Microcirculation, 71, 103-112. https://doi.org/10.3233/CH-180426
|
[110]
|
Andreassen, C.S., Jensen, J.M., Jakobsen, J., Ulhøj, B.P. and Andersen, H. (2014) Striated Muscle Fiber Size, Composition, and Capillary Density in Diabetes in Relation to Neuropathy and Muscle Strength. Journal of Diabetes, 6, 462-471. https://doi.org/10.1111/1753-0407.12124
|
[111]
|
Diaz-Morales, N., Rovira-Llopis, S., Escribano-Lopez, I., Bañuls, C., Lopez-Domenech, S., Falcón, R., de Maranon, A.M., Sola, E., Jover, A., Roldan, I., Diez, J.L., Rocha, M., Hernández-Mijares, A. and Víctor, V.M. (2016) Role of Oxidative Stress and Mitochondrial Dysfunction in Skeletal Muscle in Type 2 Diabetic Patients. Current Pharmaceutical Design, 22, 2650-2656. https://doi.org/10.2174/1381612822666160217142949
|
[112]
|
Ławnicki, J., Hansdorfer-Korzon, R. and Myśliwiec, M. (2019) Alterations in Postural Control, Gait Pattern, and Muscle Function in Diabetes Mellitus: Does It Matter in Children and Adolescents with Type 1 Diabetes? Pediatric Endocrinology Diabetes and Metabolism, 25, 23-27. https://doi.org/10.5114/pedm.2019.84707
|
[113]
|
Orlando, G., Balducci, S., Bazzucchi, I., Pugliese, G. and Sacchetti, M. (2016) Neuromuscular Dysfunction in Type 2 Diabetes: Underlying Mechanisms and Effect of Resistance Training. Diabetes/Metabolism Research and Reviews, 32, 40-50. https://doi.org/10.1002/dmrr.2658
|
[114]
|
Orlando, G., Balducci, S., Bazzucchi, I., Pugliese, G. and Sacchetti, M. (2017) Muscle Fatigability in Type 2 Diabetes. Diabetes/Metabolism Research and Reviews, 33, e2821. https://doi.org/10.1002/dmrr.2821
|
[115]
|
Garneau, L. and Aguer, C. (2019) Role of Myokines in the Development of Skeletal Muscle Insulin Resistance and Related Metabolic Defects in Type 2 Diabetes. Diabetes & Metabolism, 45, 505-516. https://doi.org/10.1016/j.diabet.2019.02.006
|
[116]
|
Min, Y.W., Ko, E.J., Lee, J.Y. and Rhee, P.L. (2018) Impaired Neural Pathway in Gastric Muscles of Patients with Diabetes. Scientific Reports, 8, Article No. 7101. https://doi.org/10.1038/s41598-018-24147-y
|
[117]
|
Montero, D., Walther, G., Pérez-Martin, A., Vicente-Salar, N., Roche, E. and Vinet, A. (2013) Vascular Smooth Muscle Function in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetologia, 56, 2122-2133. https://doi.org/10.1007/s00125-013-2974-1
|
[118]
|
Doyon, G. and Bruemmer, D. (2016) Vascular Smooth Muscle Cell Dysfunction in Diabetes: Nuclear Receptors Channel to Relaxation. Clinical Science, 130, 1837-1839. https://doi.org/10.1042/CS20160518
|
[119]
|
Hadi, H.E., Vettor, R. and Rossato, M. (2019) Cardiomyocyte Mitochondrial Dysfunction in Diabetes and Its Contribution in Cardiac Arrhythmogenesis. Mitochondrion, 46, 6-14. https://doi.org/10.1016/j.mito.2019.03.005
|
[120]
|
Kinney, G.L., Black-Shinn, J.L., Wan, E.S., Make, B., Regan, E., Lutz, S., Soler, X., Silverman, E.K., Crapo, J., Hokanson, J.E. and the COPDGene Investigators (2014) Pulmonary Function Reduction in Diabetes with and without Chronic Obstructive Pulmonary Disease. Diabetes Care, 37, 389-395. https://doi.org/10.2337/dc13-1435
|
[121]
|
Martín-Frías, M., Lamas, A., Lara, E., Alonso, M., Ros, P., Barrio, R. (2015) Pulmonary Function in Children with Type 1 Diabetes Mellitus. Journal of Pediatric Endocrinology and Metabolism, 28, 163-169. https://doi.org/10.1515/jpem-2014-0147
|
[122]
|
Röhling, M., Pesta, D., Markgraf, D.F., Strassburger, K., Knebel, B., Burkart, V., Szendroedi, J., Müssig, K., Roden, M. and GDS Study Group (2018) Metabolic Determinants of Impaired Pulmonary Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Experimental and Clinical Endocrinology & Diabetes, 126, 584-589. https://doi.org/10.1055/a-0653-7135
|
[123]
|
Kuziemski, K., Słomiński, W. and Jassem, E. (2019) Impact of Diabetes Mellitus on Functional Exercise Capacity and Pulmonary Functions in Patients with Diabetes and Healthy Persons. BMC Endocrine Disorders, 19, Article No. 2. https://doi.org/10.1186/s12902-018-0328-1
|
[124]
|
Epstein, S., Defeudis, G., Manfrini, S., Napoli, N. and Pozzilli, P. (2016) Scientific Committee of the First International Symposium on Diabetes and Bone. Diabetes and Disordered Bone Metabolism (Diabetic Osteodystrophy): Time for Recognition. Osteoporosis International, 27, 1931-1951. https://doi.org/10.1007/s00198-015-3454-x
|
[125]
|
Keenan, H.A., Maddaloni, E. (2016) Bone Microarchitecture in Type 1 Diabetes: It Is Complicated. Current Osteoporosis Reports, 14, 351-358. https://doi.org/10.1007/s11914-016-0338-8
|
[126]
|
Kanazawa, P. and Sugimoto, T. (2018) Diabetes Mellitus-Induced Bone Fragility. Journal of Internal Medicine, 57, 2773-2785. https://doi.org/10.2169/internalmedicine.0905-18
|
[127]
|
Shanbhogue, V.V., Hansen, S., Frost, M., Brixen, K. and Hermann, A.P. (2017) Bone Disease in Diabetes: Another Manifestation of Microvascular Disease? The Lancet Diabetes & Endocrinology, 5, 827-838. https://doi.org/10.1016/S2213-8587(17)30134-1
|
[128]
|
Shah, V.N., Carpenter, R.D., Ferguson, V.L. and Schwartz, A.V. (2018) Bone Health in Type 1 Diabetes. Current Opinion in Endocrinology & Diabetes and Obesity, 25, 231-236. https://doi.org/10.1097/MED.0000000000000421
|
[129]
|
Paschou, S.A., Dede, A.D., Anagnostis, P.G., Vryonidou, A., Morganstein, D. and Goulis, D.G. (2017) Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. The Journal of Clinical Endocrinology & Metabolism, 102, 3621-3634. https://doi.org/10.1210/jc.2017-00042
|
[130]
|
Rozas-Moreno, P., Reyes-García, R., Jódar-Gimeno, E., Varsavsky, M., Luque-Fernández, I., Cortés-Berdonces, M., Muñoz-Torres, M. (2017) Recommendations on the Effect of Antidiabetic Drugs in Bone. Endocrinología, Diabetes y Nutrición, 64, 1-6. https://doi.org/10.1016/j.endinu.2016.11.001
|
[131]
|
Kheniser, K.G., Santos, C.M.P. and Kashyap, S.R. (2018) The Effects of Diabetes Therapy on Bone: A Clinical Perspective. Journal of Diabetes and Its Complications, 32, 713-719. https://doi.org/10.1016/j.jdiacomp.2018.04.005
|
[132]
|
Bahrambeigi, S., Yousefi, B., Rahimi, M. and Shafiei-Irannejad, V. (2019) Metformin; An Old Antidiabetic Drug with New Potentials in Bone Disorders. Biomedicine & Pharmacotherapy, 109, 1593-1601. https://doi.org/10.1016/j.biopha.2018.11.032
|
[133]
|
Pietschmann, P., Schernthaner, G., Stephenson, J., Lang, I. and Templ, H. (1991) Enhanced Growth Hormone Responses to Growth Hormone Releasing Hormone in Male Type I Diabetic Patients. Hormone and Metabolic Research, 23, 379-382. https://doi.org/10.1055/s-2007-1003705
|
[134]
|
Trümper, B.G., Reschke, K. and Molling, J. (1995) Circadian Variation of Insulin Requirement in Insulin Dependent Diabetes Mellitus the Relationship between Circadian Change in Insulin Demand and Diurnal Patterns of Growth Hormone, Cortisol and Glucagon during Euglycemia. Hormone and Metabolic Research, 27, 141-147. https://doi.org/10.1055/s-2007-979926
|
[135]
|
Campbell, P.J., Bolli, G.B., Cryer, P.E. and Gerich, J.E. (1985) Pathogenesis of the Dawn Phenomenon in Patients with Insulin-Dependent Diabetes Mellitus. Accelerated Glucose Production and Impaired Glucose Utilization due to Nocturnal Surges in Growth Hormone Secretion. The New England Journal of Medicine, 312, 1473-1479. https://doi.org/10.1056/NEJM198506063122302
|
[136]
|
Jenni, S., Christ, E.R. and Stettler, C. (2010) Exercise-Induced Growth Hormone Response in Euglycaemia and Hyperglycaemia in Patients with Type 1 Diabetes Mellitus. Diabetic Medicine, 27, 230-233. https://doi.org/10.1111/j.1464-5491.2009.02893.x
|
[137]
|
Nambam, B. and Schatz, D. (2018) Growth Hormone and Insulin-Like Growth Factor-I Axis in Type 1 Diabetes. Growth Hormone & IGF Research, 38, 49-52. https://doi.org/10.1016/j.ghir.2017.12.005
|
[138]
|
Joseph, J.J. and Golden, S.H. (2016) Cortisol Dysregulation: The Bidirectional Link between Stress, Depression, and Type 2 Diabetes Mellitus. Annals of the New York Academy of Sciences, 1391, 20-34. https://doi.org/10.1111/nyas.13217
|
[139]
|
Raff, H. and Magill, S.B. (2016) Is the Hypothalamic-Pituitary-Adrenal Axis Disrupted in Type 2 Diabetes Mellitus? Endocrine, 54, 273-275. https://doi.org/10.1007/s12020-016-1108-1
|
[140]
|
Tirabassi, G., Corona, G., Lamonica, G.R., Lenzi, A., Maggi, M. and Balercia, G. (2016) Diabetes Mellitus-Associated Functional Hypercortisolism Impairs Sexual Function in Male Late-Onset Hypogonadism. Hormone and Metabolic Research, 48, 48-53. https://doi.org/10.1055/s-0035-1548870
|
[141]
|
Maresch, C.C., Stute, D.C., Alves, M.G., Oliveira, P.F., de Kretser, D.M. and Linn, T. (2018) Diabetes-Induced Hyperglycemia Impairs Male Reproductive Function: A Systematic Review. Human Reproduction Update, 24, 86-105. https://doi.org/10.1093/humupd/dmx033
|
[142]
|
Vignera, L.S., Condorelli, R.A., Mauro, D.M., Presti, L.D., Mongioì, L.M., Russo, G. and Calogero, A.E. (2015) Reproductive Function in Male Patients with Type 1 Diabetes Mellitus. Andrology, 3, 1082-1087. https://doi.org/10.1111/andr.12097
|
[143]
|
Kabadi, U.M. (1986) Serum T3 and Reverse T3 Concentrations: Indices of Metabolic Control in Diabetes Mellitus. Diabetes Research, 3, 417-421.
|
[144]
|
Kabadi, U.M. (1984) Altered Thyrotropin Secretion in Uncontrolled Type II Diabetes Mellitus and Its Normalization on Attainment of Eumetabolic State. The Journal of Clinical Endocrinology & Metabolism, 59, 521-525. https://doi.org/10.1210/jcem-59-3-521
|
[145]
|
Schnack, C. and Schernthaner, G. (1987) Pituitary Thyrotroph Function and Thyroid Hormones in Longstanding Type-II Diabetes Mellitus before and after Insulin Treatment. Experimental and Clinical Endocrinology & Diabetes, 90, 243-248. https://doi.org/10.1055/s-0029-1210696
|
[146]
|
Custro, N., Scafidi, V. and Borsellino, T. (1991) Changes in the Thyroid Hormone Picture That May Be Found in Severely Decompensated Type II Diabetics. Minerva Medica, 82, 9-14.
|
[147]
|
Sharma, S. and Kabadi, U.M. (2008) Euthyroid Sick Syndrome. Primary Care Reports, 14, 1-12.
|
[148]
|
Orlická, E., Vondra, K., Hill, M., Skibová, J., Sterzl, I. and Zamrazil, V. (2008) TRH Test in Patients with Diabetes Mellitus Type 1 and/or Autoimmune Thyroiditis. Changes in the Pituitary-Thyroid Axis, Reverse T3, Prolactin and Growth Hormone Levels. Physiological Research, 57, S109-S117.
|
[149]
|
Neto, A.M., Parisi, M.C.R., Tambascia, M.A., Alegre, S.M., Pavin, E.J. and Zantut-Wittmann, D.E. (2013) The Influence of Body Mass Index and Low-Grade Systemic Inflammation on Thyroid Hormone Abnormalities in Patients with Type 2 Diabetes. Endocrine Journal, 60, 877-884.
|
[150]
|
Kouidhi, S., Berhouma, R., Ammar, M., Rouissi, K., Jarboui, S., Clerget-Froidevaux, M.S., Seugnet, I., Abid, H., Bchir, F., Demeneix, B., Guissouma, H. and Elgaaied, A.B. (2013) Relationship of Thyroid Function with Obesity and Type 2 Diabetes in Euthyroid Tunisian Subjects. Endocrine Research, 38, 15-23. https://doi.org/10.3109/07435800.2012.699987
|
[151]
|
Liu, F., Di, J., Yu, H., Han, J., Bao, Y. and Jia, W. (2017) Effect of Rouxen-Y Gastric Bypass on Thyroid Function in Euthyroid Patients with Obesity and Type 2 Diabetes. Surgery for Obesity and Related Diseases, 13, 1701-1707. https://doi.org/10.1016/j.soard.2017.06.001
|
[152]
|
Mirboluk, A.A., Rohani, F., Asadi, R. and Eslamian, M.R. (2017) Thyroid Function Test in Diabetic Ketoacidosis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 11, S623-S625. https://doi.org/10.1016/j.dsx.2017.04.015
|
[153]
|
Qin, K., Zhang, F., Wu, Q., Liu, Z., Huang, Y., Tan, J., Zhou, Y., An, Z., Li, S. and Li, S. (2020) Thyroid Hormone Changes in Euthyroid Patients with Diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 2533-2540. https://doi.org/10.2147/DMSO.S260039
|
[154]
|
Condorelli, R.A., Calogero, A.E., di Mauro, M., Mongioi’, L.M., Cannarella, R., Rosta, G. and la Vignera, S. (2018) Androgen Excess and Metabolic Disorders in Women with PCOS: Beyond the Body Mass Index. Journal of Endocrinological Investigation, 41, 383-388. https://doi.org/10.1007/s40618-017-0762-3
|
[155]
|
Łagowska, K., Bajerska, J. and Jamka, M. (2018) The Role of Vitamin D Oral Supplementation in Insulin Resistance in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 10, 1637. https://doi.org/10.3390/nu10111637
|
[156]
|
Wiweko, B., Indra, I., Susanto, C., Natadisastra, M. and Hestiantoro, A. (2018) The Correlation between Serum AMH and HOMA-IR among PCOS Phenotypes. BMC Research Notes, 11, Article No. 114. https://doi.org/10.1186/s13104-018-3207-y
|
[157]
|
Alan, M., Gurlek, B., Yilmaz, A., Aksit, M., Aslanipour, B., Gulhan, I., Mehmet, C. and Taner, C.E. (2019) Asprosin: A Novel Peptide Hormone Related to Insulin Resistance in Women with Polycystic Ovary Syndrome. Gynecological Endocrinology, 35, 220-223. https://doi.org/10.1080/09513590.2018.1512967
|
[158]
|
Zhang, D., Yang, X., Li, J., Yu, J. and Wu, X. (2019) Effect of Hyperinsulinaemia and Insulin Resistance on Endocrine, Metabolic and Fertility Outcomes in Women with Polycystic Ovary Syndrome Undergoing Ovulation Induction. Clinical Endocrinology, 91, 440-448. https://doi.org/10.1111/cen.14050
|
[159]
|
Grossmann, M. (2018) Hypogonadism and Male Obesity: Focus on Unresolved Questions. Clinical Endocrinology, 89, 11-21. https://doi.org/10.1111/cen.13723
|
[160]
|
Dhindsa, S., Ghanim, H., Batra, M. and Dandona, P. (2018) Hypogonadotropic Hypogonadism in Men with Diabesity. Diabetes Care, 41, 1516-1525. https://doi.org/10.2337/dc17-2510
|
[161]
|
Molina-Vega, M., Muñoz-Garach, A., Damas-Fuentes, M., Fernández-García, J.C. and Tinahones, F.J. (2018) Secondary Male Hypogonadism: A Prevalent but Overlooked Comorbidity of Obesity. Asian Journal of Andrology, 20, 531-538. https://doi.org/10.4103/aja.aja_44_18
|
[162]
|
Giagulli, V.A., Castellana, M., Murro, I., Pelusi, C., Guastamacchia, E., Triggiani, V. and de Pergola, G. (2019) The Role of Diet and Weight Loss in Improving Secondary Hypogonadism in Men with Obesity with or without Type 2 Diabetes Mellitus. Nutrients , 11, 2975. https://doi.org/10.3390/nu11122975
|
[163]
|
Rigon, F.A., Ronsoni, M.F., Hohl, A. and van de Sande-Lee, S. (2019) Effects of Bariatric Surgery in Male Obesity-Associated Hypogonadism. Obesity Surgery, 29, 2115-2125. https://doi.org/10.1007/s11695-019-03829-0
|
[164]
|
Kabadi, U.M., Mehamood, H., Gilson, S. and Fox, I. (1995) Glycoslated Hemoglobin Concentration in Critical Illness. Journal of Diabetes Research, 28, 1-8.
|
[165]
|
Kabadi, U.M. (1998) Hood: Increased Glycation of Hemoglobin in AIDS: Relation to Severity of the Disorder. Journal of Diabetes Research, 33, 37-44.
|
[166]
|
Kabadi, U.M. (2008) Elevated Fructosamine in AIDS. Endocrine Practice, 14, 686-690. https://doi.org/10.4158/EP.14.6.686
|
[167]
|
Kabadi, U.M., Reust, C., and Kabadi, M.U. (2000) Weight Gain, Improvement in Metabolic Profile and Immunogenicity with Insulin Administration in AIDS. AIDS Patient Care and STDs, 14, 575.
|
[168]
|
Bahrambeigi, S. and Shafiei-Irannejad, V. (2020) Immune-Mediated Anti-Tumor Effects of Metformin; Targeting Metabolic Reprogramming of T Cells as a New Possible Mechanism for Anti-Cancer Effects of Metformin. Biochemical Pharmacology, 174, 113787. https://doi.org/10.1016/j.bcp.2019.113787
|
[169]
|
Shafiei-Irannejad, V., Samadi, N., Salehi, R., Yousefi, B. and Zarghami, N. (2017) New Insights into Antidiabetic Drugs: Possible Applications in Cancer Treatment. Chemical Biology & Drug Design, 90, 1056-1066. https://doi.org/10.1111/cbdd.13013
|
[170]
|
Bahrambeigi, S., Badalzadeh, R., Shafiei-Irannejad, V. and Alizadeh, A. (2019) Possible Protective Effects of Thiazolidinediones Antidiabetic Drugs in Colorectal Cancer. Critical Reviews™ in Oncogenesis, 24, 251-258. https://doi.org/10.1615/CritRevOncog.2019031265
|
[171]
|
Kabadi, U.M. and Kabadi, M.U. (2004) Weight Gain, Improvements in Metabolic Profiles and Immunogenicity with Insulin or Sulphonylurea Administration in AIDS. Clinical Drug Investigation, 24, 287-294. https://doi.org/10.2165/00044011-200424050-00005
|
[172]
|
Eringa, E.C., Serne, E.H., Meijer, R.I., Schalkwijk, C.G., Houben, A.J., Stehouwer, C.D., Smulders, Y.M. and van Hinsbergh, V.W.M. (2013) Endothelial Dysfunction in (pre)Diabetes: Characteristics, Causative Mechanisms and Pathogenic Role in Type 2 Diabetes. Reviews in Endocrine and Metabolic Disorders, 14, 39-48. https://doi.org/10.1007/s11154-013-9239-7
|
[173]
|
de Albuquerque do Nascimento, A.M.M., Sequeira, I.J., Vasconcelos, D.F., Gandolfi, L., Pratesi, R. and de Medeiros Nóbrega, Y.K. (2017) Endothelial Dysfunction in Children with Type 1 Diabetes Mellitusarch. Archives of Endocrinology and Metabolism, 61, 476-483. https://doi.org/10.1590/2359-3997000000271
|
[174]
|
Goligorsky, M.S. (2017) Vascular Endothelium in Diabetes. American Journal of Physiology Renal Physiology, 312, F266-F275. https://doi.org/10.1152/ajprenal.00473.2016
|
[175]
|
Shi, Y. and Vanhoutte, P.M. (2017) Macro- and Microvascular Endothelial Dysfunction in Diabetes. Journal of Diabetes, 9, 434-449. https://doi.org/10.1111/1753-0407.12521
|
[176]
|
Galvan, D.L., Green, N.H. and Danesh, F.R. (2017) The Hallmarks of Mitochondrial Dysfunction in Chronic Kidney Disease. Kidney International, 92, 1051-1057. https://doi.org/10.1016/j.kint.2017.05.034
|
[177]
|
Kaur, R., Kaur, M. and Singh, J. (2018) Endothelial Dysfunction and Platelet Hyperactivity in Type 2 Diabetes Mellitus: Molecular Insights and Therapeutic Strategies. Cardiovascular Diabetology, 17, Article No. 121. https://doi.org/10.1186/s12933-018-0763-3
|
[178]
|
Knapp, M., Tu, X. and Wu, R. (2019) Vascular Endothelial Dysfunction, a Major Mediator in Diabetic Cardiomyopathy. Acta Pharmacologica Sinica, 40, 1-8. https://doi.org/10.1038/s41401-018-0042-6
|
[179]
|
Lightman, S. (1993) Does Aldose Reductase Have a Role in the Development of the Ocular Complications of Diabetes? Eye, 7, 238-241. https://doi.org/10.1038/eye.1993.56
|
[180]
|
Jocelyn, J., Drinkwater, Davis, W.A. and Davis, T.M.E. (2019) A Systematic Review of Risk Factors for Cataract in Type 2 Diabetes. Diabetes/Metabolism Research and Reviews, 35, e3073. https://doi.org/10.1002/dmrr.3073
|
[181]
|
Hashim, Z. and Zarina, S. (2012) Osmotic Stress Induced Oxidative Damage: Possible Mechanism of Cataract Formation in Diabetes. Journal of Diabetes and its Complications , 26, 275-279. https://doi.org/10.1016/j.jdiacomp.2012.04.005
|
[182]
|
Maccari, R. and Ottanà, R. (2015) Targeting Aldose Reductase for the Treatment of Diabetes Complications and Inflammatory Diseases: New Insights and Future Directions. Journal of Medicinal Chemistry, 58, 2047-2067. https://doi.org/10.1021/jm500907a
|
[183]
|
Huang, Q., Liu, Q. and Ouyang, D. (2019) Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications. Medicinal Chemistry, 15, 3-7. https://doi.org/10.2174/1573406414666180524082445
|
[184]
|
Quattrini, L. and la Motta, C. (2019) Aldose Reductase Inhibitors: 2013-Present. Expert Opinion on Therapeutic Patents, 29, 199-213. https://doi.org/10.1080/13543776.2019.1582646
|
[185]
|
Vlassara, H. and Striker, G.E. (2013) Advanced Glycation Endproducts in Diabetes and Diabetic Complications. Endocrinology and Metabolism Clinics of North America, 42, 697-719. https://doi.org/10.1016/j.ecl.2013.07.005
|
[186]
|
Brings, S., Fleming, T., Freichel, M., Muckenthaler, M.U., Herzig, S. and Nawroth, P.P. (2017) Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention. International Journal of Molecular Science, 18, 984. https://doi.org/10.3390/ijms18050984
|
[187]
|
Simó-Servat, O., Planas, A., Ciudin, A., Simó, R. and Hernández, C. (2018) Assessment of Advanced Glycation End-Products as a Biomarker of Diabetic Outcomes. Endocrinología, Diabetes y Nutrición, 65, 540-545. https://doi.org/10.1016/j.endinu.2018.06.003
|
[188]
|
Shen, H., Zhao, J., Liu, Y. and Sun, G. (2018) Interactions between and Shared Molecular Mechanisms of Diabetic Peripheral Neuropathy and Obstructive Sleep Apnea in Type 2 Diabetes Patients. Journal of Diabetes Research, 2018, Article ID: 3458615. https://doi.org/10.1155/2018/3458615
|
[189]
|
Banarjee, R., Sharma, A., Bai, S., Deshmukh, A. and Kulkarni, M. (2018) Proteomic Study of Endothelial Dysfunction Induced by AGEs and Its Possible Role in Diabetic Cardiovascular Complications. Journal of Proteomics, 187, 69-79. https://doi.org/10.1016/j.jprot.2018.06.009
|
[190]
|
Mori, H., Kuroda, A., Ishizu, M., Ohishi, M., Takashi, Y., Otsuka, Y., Taniguchi, S., Tamaki, M., Kurahashi, K., Yoshida, S., Endo, I., Aihara, K.I., Funaki, M., Akehi, Y. and Matsuhisa, M. (2019) Association of Accumulated Advanced Glycation End-Products with a High Prevalence of Sarcopenia and Dynapenia in Patients with Type 2 Diabetes. Journal of Diabetes Investigation, 10, 1332-1340. https://doi.org/10.1111/jdi.13014
|
[191]
|
Qiu, S., Cai, X., Yin, H., Sun, Z., Zügel, M., Steinacker, J.M. and Schumann, U. (2018) Exercise Training and Endothelial Function in Patients with Type 2 Diabetes: A Meta-Analysis. Cardiovascular Diabetology, 17, Article No. 64. https://doi.org/10.1186/s12933-018-0711-2
|
[192]
|
The Diabetes Control and Complications Trial Research Group (1993) The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. The New England Journal of Medicine, 329, 977-986. https://doi.org/10.1056/NEJM199309303291401
|
[193]
|
Kabadi, U.M. (1999) DCCT: Medical and Economical Message, Five Years Later. Experimental and Clinical Endocrinology & Diabetes, 107, S24-S29. https://doi.org/10.1055/s-0029-1212146
|
[194]
|
Nathan, D.M. and DCCT/EDIC Research Group (2014) The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care, 37, 9-16. https://doi.org/10.2337/dc13-2112
|
[195]
|
Diabetes Control and Complications Trial [DCCT]/Epidemiology of Diabetes Interventions and Complications [EDIC] Study Research Group (2016) Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-Up. Diabetes Care, 39, 686-693. https://doi.org/10.2337/dc15-1990
|
[196]
|
Diabetes Control and Complications Trial [DCCT]/Epidemiology of Diabetes Interventions and Complications [EDIC] Study Research Group (2016) Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population. Diabetes Care, 39, 1378-1383. https://doi.org/10.2337/dc15-2399
|
[197]
|
Bebu, I., Braffett, B.H., Orchard, T.J., Lorenzi, G.M., Lachin, J.M. and DCCT/EDIC Research Group (2019) Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 42, 1284-1289. https://doi.org/10.2337/dc18-1613
|
[198]
|
Testa, R., Bonfigli, A.R., Prattichizzo, F., la Sala, L., De Nigris, V. and Ceriello, A. (2017) The “Metabolic Memory” Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications. Nutrients, 9, 437. https://doi.org/10.3390/nu9050437
|
[199]
|
Miller, R.G. and Orchard, T.J. (2020) Understanding Metabolic Memory: A Tale of Two Studies. Diabetes, 69, 291-299. https://doi.org/10.2337/db19-0514
|
[200]
|
Chalmers, J. and Cooper, M.E. (2008) UKPDS and the Legacy Effect. The New England Journal of Medicine, 359, 1618-1620. https://doi.org/10.1056/NEJMe0807625
|
[201]
|
Laiteerapong, N., Ham, S.A., Gao, Y., Moffet, H.H., Liu, J.Y., Huang, E.S. and Karter, A.J. (2019) The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care, 42, 416-426. https://doi.org/10.2337/dc17-1144
|
[202]
|
Qiu, S., Cai, X., Yin, H., Sun, Z., Zügel, M., Steinacker, J.M., Schumann, U. and Scheen, A.J. (2019) Effects of Glucose-Lowering Agents on Surrogate Endpoints and Hard Clinical Renal Outcomes in Patients with Type 2 Diabetes. Diabetes & Metabolism, 45, 110-121. https://doi.org/10.1016/j.diabet.2018.10.003
|
[203]
|
Chhipa, A.S., Borse, S.P., Baksi, R., Lalotra, S. and Nivsarkar, M. (2019) Targeting Receptors of Advanced Glycation End Products (RAGE): Preventing Diabetes Induced Cancer and Diabetic Complications. Pathology—Research and Practice, 215, Article ID: 152643. https://doi.org/10.1016/j.prp.2019.152643
|